Research output per year
Research output per year
Personal profile
Expertises
Haemato-oncologist. Responsible for treatment of malignant lymphoma and for experimental/phase I treatment of haematological malignancies at Rigshospitalet. Head of service for Hodgkin lymphoma, Mantle cell lymphoma and Castleman’s disease.
Main research areas
Hodgkin lymphoma; Mantle cell lymphoma; PET/CT in lymphoma; PET-response adapted lymphoma treatment; Phase 1 haematology studies;
Current research
Chairman of the EORTC lymphoma group since 2013. Co-author of the international response criteria and guidelines for the use of imaging in lymphoma. Co-author of the European society of Medical Oncology (ESMO) guidelines for Hodgkin lymphoma and ’ultra high-risk’ lymphomas.
Faculty member for the EHA Clinical Research Training in Haematology programme
Member of the scientific committee for the European Haematology Association
National principal investigator or sub-investigator for >25 solid tumour and haematology phase I trials
National principal investigator for three mantle cell lymphoma trials (one ongoing and two planned) and three Hodgkin lymphoma trials.
Site principal investigator or sub-investigator for >20 lymphoma and myeloma phase II and phase III trials
Potential conflicts of interest
None
Fingerprint
Dive into the research topics where Martin Hutchings is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives
Prince, H. M., Hutchings, M., Domingo-Domenech, E., Eichenauer, D. A. & Advani, R., Jan 2023, In: Annals of Hematology. 102, 1, p. 13-29 17 p.Research output: Contribution to journal › Review › peer-review
-
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial
Fornecker, L-M., Lazarovici, J., Aurer, I., Casasnovas, R-O., Gac, A-C., Bonnet, C., Bouabdallah, K., Feugier, P., Specht, L., Molina, L., Touati, M., Borel, C., Stamatoullas, A., Nicolas-Virelizier, E., Pascal, L., Lugtenburg, P., Di Renzo, N., Vander Borght, T., Traverse-Glehen, A., Dartigues, P., & 6 others, 10 Jan 2023, In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 41, 2, p. 327-335 9 p.Research output: Contribution to journal › Journal article › Research › peer-review
-
ABCL-422 Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study
Thieblemont, C., Phillips, T., Ghesquieres, H., Cheah, C. Y., Clausen, M. R., Cunningham, D., Do, Y. R., Feldman, T., Gasiorowski, R., Jurczak, W., Kim, T. M., Lewis, D. J., van der Poel, M., Poon, M. L., Doerr, T., Kilavuz, N., Chen, M., Sacchi, M., Elliott, B., Hutchings, M., & 1 others, Oct 2022, In: Clinical Lymphoma, Myeloma & Leukemia. 22 Suppl 2, p. S379Research output: Contribution to journal › Journal article › Research › peer-review
-
An Epidemiological Model to Estimate the Prevalence of Diffuse Large B-Cell Lymphoma in the United States
Chihara, D., Johnston, K., Bolatova, T., Szabo, S., Kalsekar, A., Mutebi, A., Yang, H., Liu, Y., Attinson, D. & Hutchings, M., Dec 2022, In: Clinical Lymphoma, Myeloma & Leukemia. 22, 12, p. e1092-e1099Research output: Contribution to journal › Journal article › Research › peer-review
-
Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL
Husby, S., Bæch-Laursen, C., Eskelund, C. W., Favero, F., Jespersen, J. S., Hutchings, M., Pedersen, L. B., Niemann, C. U., Weischenfeldt, J., Räty, R., Larsen, T. S., Kolstad, A., Jerkeman, M. & Grønbæk, K., Dec 2022, In: Leukemia. 36, 12, p. 2912-2916 5 p.Research output: Contribution to journal › Letter › peer-review